Moderna announces that preliminary clinical trial data confirms that its vaccine Updated COVID-19 for the fall 2023 vaccination season shows a significant increase in neutralizing antibodies against EG.5 and FL.1.5.1 variants. The World Health Organization (WHO) recently classified the EG.5 strain. as a variant of interest. According to the Centers for Disease Control and Prevention (CDC), EG.5 is now the dominant variant in the United States and also accounts for a growing proportion of cases worldwide. However, the FL 1.5.1 variant is also starting to circulate in some parts of the country.
The company has submitted its updated COVID-19 vaccine to the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other regulatory bodies around the world and expects it to be ready for the autumn vaccination campaign with a large and punctual supply.
“These new results, which demonstrate that our updated COVID-19 vaccine generates a robust immune response against the EG.5 and FL 1.5.1 strains, which are spreading rapidly, and reflects the ability of our updated vaccine to address the emerging threats of COVID-19. Moderna is committed to leveraging our mRNA technology to provide healthcare security around the world,” said Stephen Hoge, President of Moderna.
In addition to demonstrating a human immune response against the EG.5 and FL 1.5.1 strains, Moderna previously presented the only clinical trial data confirming that its updated vaccine displays robust human immune responses across the key circulating XBB strains in the VRBPAC. from the FDA June 2023. With these new assay data, Moderna has now confirmed an antibody response against the current strains of interest..
Agreement with the URJC
At the beginning of July, the company formalized a collaboration agreement with the King Juan Carlos University (URJC) with the aim of generating new scientific evidence around the messenger RNA platform. For this reason, they created the ‘Modern Chair-URJC in Epidemiology of Infectious Diseases’ with a validity of two years, extendable up to four years.
The new Chair will allow both parties to work together on the design of a training program aimed at generating knowledge and contributing to the advancement of science and medicine. Specifically, through the study of mRNA vaccines against COVID-19 and their effects on the immunocompromised population and on patients hospitalized for the disease. Both parties aim to implement and develop research and teaching activities, as well as projects associated with the Chair.
You may also like…
2023-08-21 07:10:30
#Moderna #announces #updated #vaccine #COVID19 #generates #immune #response #circulating #variants
